$dcth
Delcath Systems sees a massive surge in social engagements, driven by discussions around its FDA-approved liver cancer treatment and potential expansion into new indications. However, concerns linger regarding MedTech sector risks and a management blackout period.
About $dcth
Delcath Systems is a medical technology company specializing in cancer treatments, particularly for liver cancers.
Insights
- $dcth engagements is up 1672.12% from the previous week.
Engagements: [---] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [------]
[--] Week: [-----] +1,672%
[--] Month: [------] -70%
[--] Months: [---------] -33%
[--] Year: [---------] +60%
1-Year High: [-------] on 2025-03-05
1-Year Low: [---] on 2025-04-22
Engagements by network (24h): Reddit: [--] YouTube: [--] X: [---]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-22
1-Year Low: [--] on 2025-09-14
Mentions by network (24h): Reddit: [--] YouTube: [--] X: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $dcth in the last [--] hours which is down 15% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-04-12
The most influential creators that mention $dcth in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Fund_Stocks | [--] | [--] | [--] | [--] |
| @NightOwlBiotech | [--] | [-----] | [--] | [--] |
| @PeterMallouk | [--] | [-----] | [--] | [--] |
Sentiment: 50%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 50%
Daily Average: 84%
[--] Week: 67% -33%
[--] Month: 25% -15%
[--] Months: 25% -75%
[--] Year: 25% -75%
1-Year High: 100% on 2025-02-18
1-Year Low: 9% on 2025-12-18
Most Supportive Themes:
- FDA-Approved Product and Revenue Story: (25%) Delcath has an FDA-approved product, HEPZATO KIT, for liver-dominant uveal melanoma, positioning it as a revenue-generating company rather than a preclinical one.
- Expansion into New Indications: (20%) Management is targeting additional indications for their platform, such as colorectal liver metastases, which could lead to a high-margin franchise.
- Undervalued with Upcoming Catalysts: (20%) The company is considered undervalued with anticipated catalysts, attracting investors looking for potential growth opportunities.
- Long-term Hold Potential: (15%) The stock is viewed as a long-term hold due to its unique position in the MedTech space, offering a contrast to the higher risks associated with biotech.
- Informative Podcast Discussion: (10%) A podcast discussed the Chopin trial, providing informative insights into the company's developments.
Most Critical Themes:
- MedTech Risks: (50%) While distinct from biotech risks, the company operates within the MedTech sector, which inherently carries its own set of risks.
- Management Blackout Period: (50%) Potential weakness in the stock may be linked to management entering a blackout period, which could pause buyback activities.
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing